

**Clinical Policy: Sodium Phenylbutyrate/Taurursodiol (Relyvrio)**

Reference Number: CP.PHAR.584

Effective Date: 09.29.22

Last Review Date: 05.25

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Sodium phenylbutyrate/taurursodiol (Relyvrio™) is coformulation of the compounds sodium phenylbutyrate, a molecular chaperone, and taurursodiol, a Bax inhibitor.

**FDA Approved Indication(s)**

Relyvrio is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation® that Relyvrio is **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria****A. Amyotrophic Lateral Sclerosis (must meet all):**

1. Authorization is not permitted. Member may not initiate therapy with Relyvrio. The manufacturer voluntarily discontinued the marketing authorization for Relyvrio and initiated its removal from the market. Relyvrio was no longer available for new patients as of April 4, 2024 (*see Appendix F*).

**Approval duration: Not applicable**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line

of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

## II. Continued Therapy

### A. Amyotrophic Lateral Sclerosis (must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy (e.g., no tracheostomy or permanent assisted ventilation);
3. If the member wishes to continue using Relyvrio, in consultation with their physician, the member may be authorized for continued therapy up to 1 month after which they can be transitioned to a free drug program per the manufacturer (*see Appendix F*);
4. If request is for a dose increase, new dose does not exceed 6 g sodium phenylbutyrate/2 g taurursodiol (2 packets) per day.

**Approval duration: 1 month**

### B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

## III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

ALS: amyotrophic lateral sclerosis	LMN: lower motor neuron
EMG: electromyography	SVC: slow vital capacity
FDA: Food and Drug Administration	UMN: upper motor neuron disease

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
riluzole (Rilutek <sup>®</sup> )	50 mg PO BID	100 mg/day

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

None reported

*Appendix D: General Information*

- Revised El Escorial diagnostic criteria for ALS requires the presence of:
  1. Signs of lower motor neuron (LMN) degeneration by clinical, electrophysiological or neuropathologic examination,
  2. Signs of upper motor neuron (UMN) degeneration by clinical examination, and
  3. Progressive spread of symptoms or signs within a region or to other regions, together with the absence of:
    - a. Electrophysiological evidence of other disease processes that might explain the signs of LMN and/or UMN degenerations; and
    - b. Neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological signs.
- The definitions of ALS diagnoses provided by the revised El Escorial criteria are as follows:

Revised El Escorial criteria	
<b>Clinically definite ALS</b>	Clinical evidence alone of UMN and LMN signs in $\geq 3$ regions
<b>Clinically probable ALS</b>	Clinical evidence alone of UMN and LMN signs in $\geq 2$ regions with some UMN signs rostral to (above) LMN signs
<b>Clinically probable lab-supported ALS</b>	Clinical signs of UMN and LMN dysfunction in 1 region OR UMN signs in 1 region, and LMN signs defined by EMG criteria in $\geq 2$ regions
<b>Clinically possible ALS</b>	Clinical signs of UMN and LMN dysfunction in 1 region OR Isolated UMN signs in $\geq 2$ regions OR LMN signs rostral to UMN signs

*Appendix E: Riluzole Co-administration*

There is support for the co-administration of riluzole in ALS:

- The 2009 American Academy of Neurology ALS guideline for the care of the patient with ALS (reaffirmed February 2023) recommends that riluzole should be offered to slow disease progression (Level A).
- The 2020 Canadian best practice recommendations for the management of ALS state the following: riluzole has demonstrated efficacy in improving survival in ALS (level A), there is evidence that riluzole prolongs survival by a median duration of 3 months (level A), and riluzole should be started soon after the diagnosis of ALS (expert consensus).
- Additionally, approximately 71% of patients in the phase 2 CENTAUR trial were receiving concomitant riluzole.

*Appendix F: Withdrawal of Relyvrio from the US Market*

- On April 4, 2024, Amylyx Pharmaceuticals announced the decision to voluntarily discontinue the marketing authorization for Relyvrio and remove the product from the market based on topline results from the phase 3 PHOENIX trial. PHOENIX did not meet its primary endpoint of reaching statistical significance ( $p = 0.667$ ) as measured by change from baseline in the Revised ALS Functional Rating Scale (ALSFRS-R) total score at Week 48, nor was there statistical significance seen in secondary endpoints. Relyvrio will no longer be available for new patients as of April 4, 2024.
- Action required for prescribers: physicians should not initiate new treatment with Relyvrio, effective April 4, 2024. Patients currently on therapy who, in consultation with their physician, wish to stay on treatment can be transitioned to a free drug program.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
ALS	1 packet (3 g sodium phenylbutyrate and 1 g taurursodiol) daily for the first 3 weeks, followed by 1 packet twice daily thereafter	2 packets (6 g sodium phenylbutyrate and 2 g taurursodiol) per day

**VI. Product Availability**

Powder for oral suspension: 3 g of sodium phenylbutyrate and 1 g of taurursodiol in single dose packet

**VII. References**

1. Relyvrio Prescribing Information. Cambridge, MA: Amylyx Pharmaceuticals; September 2022. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/216660s0001bledt.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s0001bledt.pdf). Accessed January 16, 2025.
2. Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. *N Engl J Med*. 2020 Sep 3;383(10):919-930.
3. Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. *Muscle Nerve*. 2021 Jan;63(1):31-39.

4. Paganoni S, Hendrix S, Dickson SP, et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. *J Neurol Neurosurg Psychiatry*. 2022;93(8):871-875.
5. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2000 Dec;1(5):293-9.
6. Shoosmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. *CMAJ*. 2020 Nov;192(46):E1453-E1468.
7. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2009 Oct 13 (reaffirmed February 2023);73(15):1218-26.
8. Amylyx Pharmaceuticals press release. Amylyx pharmaceuticals announces formal intention to remove Relyvrio<sup>®</sup>/Albrioza<sup>™</sup> from the market; provides updates on access to therapy, pipeline, corporate restructuring, and strategy. Available at: <https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior/albrioza™-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy>. Accessed February 20, 2025.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	04.05.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	09.19.22	
RT4: Drug is now FDA approved – criteria updated per FDA labeling; added maximum dose of 2 packets/day; added no tracheostomy or permanent assisted ventilation as examples of positive response; references reviewed and updated.	10.06.22	
2Q 2023 annual review: no significant changes; references reviewed and updated.	02.03.23	05.23
2Q 2024 annual review: no significant changes; updated Appendix D table of revised El Escorial criteria; references reviewed and updated. Removed initial approval criteria and limited continued authorization to 1 month due to manufacturer withdrawal; added Appendix F with details of market withdrawal	04.04.24	05.24
2Q 2025 annual review: no significant changes; retaining policy as Medispan obsolete date is 11/1/26; references reviewed and updated.	02.20.25	05.25

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program

approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2022 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.